Evidence map›Paper›PMID 34767682›Full record

ArticleJournal of magnetic resonance imaging : JMRI2022

Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness.

Sean D McGarry, Michael Brehler, John D Bukowy, Allison K Lowman, Samuel A Bobholz, Savannah R Duenweg, Anjishnu Banerjee, Sarah L Hurrell, Dariya Malyarenko, Thomas L Chenevert and 34 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

44 authors at 15 institutions in 2 countries.

Sean D McGarryDepartment of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Michael BrehlerDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
John D BukowyDepartment of Electrical Engineering and Computer Science, Milwaukee School of Engineering, Milwaukee, WI, USA.
Allison K LowmanDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Samuel A BobholzDepartment of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Savannah R DuenwegDepartment of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Anjishnu BanerjeeDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Sarah L HurrellDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Dariya MalyarenkoDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Thomas L ChenevertDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Yue CaoDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Yuan LiDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Daekeun YouDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Andrey FedorovDepartment of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Laura C BellDivision of Neuroimaging Research, Barrow Neurological Institute, Phoenix, Arizona, USA.
C Chad QuarlesDivision of Neuroimaging Research, Barrow Neurological Institute, Phoenix, Arizona, USA.
Melissa A PrahDepartment of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Kathleen M SchmaindaDepartment of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Bachir TaouliDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-6409-1333
Eve LoCastroDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-3975-8153
Yousef MazaheriDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Amita Shukla-DaveDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-7456-3197
Thomas E YankeelovDepartment of Biomedical Engineering, Diagnostic Medicine, Oncology, Oden Institute for Computational Engineering and Sciences, Livestrong Cancer Institutes, The University of Texas, Austin, Texas, USA.
David A HormuthDepartment of Biomedical Engineering, Diagnostic Medicine, Oncology, Oden Institute for Computational Engineering and Sciences, Livestrong Cancer Institutes, The University of Texas, Austin, Texas, USA.
Ananth J MadhuranthakamDepartment of Radiology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Keith HulseyDepartment of Radiology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kurt LiInternational School of Beaverton, Aloha, Oregon, USA.
Wei HuangAdvanced Imaging Research Center, Oregon Health Sciences University, Portland, Oregon, USA.
Wei HuangDepartment of Pathology, Oregon Health and Science University, Madison, Wisconsin, USA.
Mark MuziDepartment of Radiology, Neurology, and Radiation Oncology, University of Washington, Seattle, Washington, USA.
Michael A JacobsThe Russell H. Morgan Department of Radiology and Radiological Science and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meiyappan SolaiyappanThe Russell H. Morgan Department of Radiology and Radiological Science and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Stefanie HectorsDepartment of biomedical engineering and imaging institute, Weill Cornell Medical College, New York City, New York, USA.
Tatjana AnticDepartment of Pathology, University of Chicago, Chicago, Illinois, USA.
Gladell P PanerDepartment of Pathology, University of Chicago, Chicago, Illinois, USA.
Watchareepohn PalangmonthipDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Kenneth JacobsohnDepartment of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Mark HohenwalterDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Petar DuvnjakDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Michael GriffinDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
William SeeDepartment of Urology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Marja T NevalainenDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Kenneth A IczkowskiDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Peter S LaVioletteDepartment of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-9602-6891
Medical College of Wisconsin · USUniversity of Michigan · USMemorial Sloan Kettering Cancer Center · USBarrow Neurological Institute · USJohns Hopkins University · USLivestrong Foundation · USOregon Health & Science University · USThe University of Texas Southwestern Medical Center · USUniversity of Chicago · USBrigham and Women's Hospital · USCarepayment (United States) · USCornell University · USIcahn School of Medicine at Mount Sinai · USMilwaukee School of Engineering · USUniversity of Washington · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Clinical and Translational Science AwardUL1TR001436 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI FREED, JULIE K · 2015 to 2025
$47.5M
QUANTITATION OF HUMAN BRAIN TUMOR THERAPY RESPONSE BY MRP01CA085878 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GALBAN, CRAIG J · 2001 to 2017
$31.9M
Image Guided Therapy Center - Ultrasound-based sensor system for the monitoring of COVID-19 patientsP41EB015898 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI TEMPANY, CLARE M · 2012 to 2021
$18.9M
Established Status Epilepticus Treatment Trial (ESETT)U01NS088034 · NINDS · UNIVERSITY OF VIRGINIA · PI CHAMBERLAIN, JAMES, KAPUR, JAIDEEP · 2014 to 2018
$16.3M
TRD 3 - Enabling Technologies for Intraprocedural GuidanceP41EB028741 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI Carl-Fredrik Westin · 2021 to 2026
$10.7M
Elimination of Instrumental Bias for Quantitative Diffusion Imaging in Clinical Oncology TrialsR01CA190299 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MALYARENKO, DARIYA I. · 2015 to 2025
$6.4M
Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer TherapyU01CA140204 · NCI · JOHNS HOPKINS UNIVERSITY · PI DU, YONG, SOLNES, LILJA · 2011 to 2022
$6.1M
Quantitative (Perfusion and Diffusion) MRI Biomarkers to Measure Glioma ResponseU01CA176110 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI SCHMAINDA, KATHLEEN MARIE · 2014 to 2023
$4.9M
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant TherapyU01CA142565 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KARCZMAR, GREGORY S., NANDA, RITA · 2010 to 2019
$4.5M
Quantitative DW-MRI for Early Breast Cancer Treatment Response AssessmentU01CA166104 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHENEVERT, THOMAS L, GALBAN, CRAIG J · 2012 to 2019
$4.1M
NCATS NIH HHS TL1 TR001437NCATS NIH HHS UL1 TR001436NCI NIH HHS P01 CA085878NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA158079NCI NIH HHS R01 CA160902NCI NIH HHS R01 CA190299NCI NIH HHS R01 CA207290NCI NIH HHS R01 CA218144NCI NIH HHS R01 CA221938NCI NIH HHS R01 CA228036NCI NIH HHS R01 CA241817NCI NIH HHS R01 CA248192NCI NIH HHS R01 CA249882NCI NIH HHS R21 CA231892NCI NIH HHS R50 CA211270NCI NIH HHS U01 CA140204NCI NIH HHS U01 CA142565NCI NIH HHS U01 CA151261NCI NIH HHS U01 CA154602NCI NIH HHS U01 CA166104NCI NIH HHS U01 CA172320NCI NIH HHS U01 CA176110NCI NIH HHS U01 CA183848NCI NIH HHS U01 CA207091NCI NIH HHS U01 CA211205NCI NIH HHS U24 CA180918NCI NIH HHS UG3 CA247606NIBIB NIH HHS P41 EB015898NIBIB NIH HHS P41 EB028741
6 · The paper itself

Abstract

backgroundDiffusion-weighted imaging (DWI) is commonly used to detect prostate cancer, and a major clinical challenge is differentiating aggressive from indolent disease. PURPOSE: To compare 14 site-specific parametric fitting implementations applied to the same dataset of whole-mount pathologically validated DWI to test the hypothesis that cancer differentiation varies with different fitting algorithms. STUDY TYPE: Prospective. POPULATION: Thirty-three patients prospectively imaged prior to prostatectomy. FIELD STRENGTH/SEQUENCE: 3 T, field-of-view optimized and constrained undistorted single-shot DWI sequence. ASSESSMENT: Datasets, including a noise-free digital reference object (DRO), were distributed to the 14 teams, where locally implemented DWI parameter maps were calculated, including mono-exponential apparent diffusion coefficient (MEADC), kurtosis (K), diffusion kurtosis (DK), bi-exponential diffusion (BID), pseudo-diffusion (BID*), and perfusion fraction (F). The resulting parametric maps were centrally analyzed, where differentiation of benign from cancerous tissue was compared between DWI parameters and the fitting algorithms with a receiver operating characteristic area under the curve (ROC AUC). STATISTICAL TEST: Levene's test, P < 0.05 corrected for multiple comparisons was considered statistically significant.

resultsThe DRO results indicated minimal discordance between sites. Comparison across sites indicated that K, DK, and MEADC had significantly higher prostate cancer detection capability (AUC range = 0.72-0.76, 0.76-0.81, and 0.76-0.80 respectively) as compared to bi-exponential parameters (BID, BID*, F) which had lower AUC and greater between site variation (AUC range = 0.53-0.80, 0.51-0.81, and 0.52-0.80 respectively). Post-processing parameters also affected the resulting AUC, moving from, for example, 0.75 to 0.87 for MEADC varying cluster size. DATA

conclusionWe found that conventional diffusion models had consistent performance at differentiating prostate cancer from benign tissue. Our results also indicated that post-processing decisions on DWI data can affect sensitivity and specificity when applied to radiological-pathological studies in prostate cancer. LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY: Stage 3.

Indexed as

Diffusion Magnetic Resonance ImagingProstatic NeoplasmsHumansMaleProspective StudiesRetrospective StudiesROC CurveSensitivity and SpecificitycancerdiffusionMRImultisite |modellingprostate

Identifiers

PMID34767682
PMCPMC9095769
OpenAlexW3213580108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.